• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Programmed polymersomes with spatio-temporal delivery of antigen and dual-adjuvants for efficient dendritic cells-based cancer immunotherapy

    2022-09-15 03:10:50HanyongWangXinyuYangChunyanHuChenluHuangHaiWangDunwanZhuLinhuaZhang
    Chinese Chemical Letters 2022年9期

    Hanyong Wang, Xinyu Yang, Chunyan Hu, Chenlu Huang, Hai Wang, Dunwan Zhu,Linhua Zhang

    Tianjin Key Laboratory of Biomedical Materials, Key Laboratory of Biomaterials and Nanotechnology for Cancer Immunotherapy, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, China

    ABSTRACT Since antigen and adjuvant are rapid clearance in vivo, insufficient delivery to induce dendritic cells (DCs)maturation and cross-presentation, as well as limited migration efficiency of DCs to secondary lymph organs, greatly hinders the development of DCs-based immunotherapy.Herein, PCL-PEG-PCL polymersomes(PCEP-PS) as antigen and adjuvants delivery nanoplatforms (IMO-PS) were well-designed, which can electrostatically adsorb OVA antigen on the surface via DOTAP lipid and effectively encapsulate OVA antigen into the inner hydrophilic cavity to achieve both initial antigen exposure as well as slow and sustained antigen release, incorporate MPLA within the lipid layer to ligate with extracellular TLR4 of DCs as well as encapsulate IMQ in the hydrophobic membrane to ligate with intracellular TLR7/8 of DCs for activating synergistic immune responses via different signaling pathways.The IMO-PS significantly improved antigen uptake, promoted DCs maturation and cytokines production.DCs treated with IMO-PS could enhance migration into draining lymphoid nodes, and eventually induced antigen-specific CD8+ and CD4+T cell responses and OVA-specific cytotoxic T lymphocyte (CTL) responses.Prophylactic vaccination of EG7-OVA tumor-bearing mice by IMO-PS+DCs significantly extended tumor-free time, effectively suppressed tumor growth, and greatly extended median survival time.The strategy may provide an effective nanoplatform for co-delivery antigen and dual-adjuvants in a spatio-temporally programmed manner for DC-based cancer immunotherapy.

    Keywords:DCs vaccine Immunotherapy Imiquimod MPLA DOTAP OVA

    As professional antigen-presenting cells, dendritic cells (DCs)play pivotal roles in both innate and adaptive immune responses[1].By processing captured antigen into peptides, DCs present them to lymphoid organs to initiate T cell or B cell immunity [2–4].Recently, DCs have been extensively used in developing DCsbased immunotherapy to treat cancer [5].DCs-based therapy includesin vitroloading of DCs with tumor or pathogen-associated antigens, activating and maturing the cells, and then reinjecting the DCs back to activate T cellsin vivo[6–8].Although DCs-based immunotherapy exhibits safety and immunogenicity, clinical responses have been largely unsatisfactory [9].There are several pitfalls restricting the effects of DCs vaccines.Among them, the main pitfall is few (~0.5%–2%) injected DCs can migrate to the lymph nodes (LNs), which hinders effective induction of T cell responses.Another drawback is inefficient stimulation of DCs to induce their maturation for the subsequent antigen-presentation to T cells, which is essential for effective DCs-based immunotherapy[1].

    Nanotechnology offers unique opportunities to tackle the clinical challenges faced by current DCs-based immunotherapy.Nanoparticles can be designed to act on DCs and regulate their functions in several distinct ways: by delivering or acting as adjuvants to optimize DCs activation, enhancing antigen internalization by targeting to DCs, facilitating exogenous antigen crosspresentationvialysosome escape, incorporating different vaccine components to help DCs to govern the activation of CD4+and CD8+T cells, or exerting intrinsic immunomodulation effect on DCs [8,10–12].Rincon-Restrepoet al.demonstrated that antigen encapsulated within the nanoparticles preferred CD4+T cell activation while antigen decorated onto the surface of NPs primarily led to CD8+T cell responses [13].Hence, nanoparticles with both surface-attached and core-encapsulated antigen might result in both CD4+and CD8+immune responses.Among various nanoparticles, polymersomes have a unique structure in which an aqueous core is enveloped by a bilayer membrane formulated by amphiphilic copolymers, entitling the vesicles with the capability of encapsulating both hydrophobic and hydrophilic molecules[14].The potential to encapsulate bioactive molecules with various physicochemical properties makes polymersomes a flexible vehicle to incorporate both antigen and adjuvants.In addition,the surface of the polymersomes can be easily further decorated with cationic lipid, which can complex with anionic peptides or proteins to generate immune responsesin vivo.1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) has been widely investigated in forming cationic liposome.DOTAP not only can adsorb anionic antigen to form vaccine carrier but also can facilitate antigen escape from the lysosome into the cytosolviaits ‘proton sponge’effect in acidic condition [15,16].Only after lysosome escape can the antigen be presentedviaMHC Ⅰpathway to activate CD8+T cells and elicit cytotoxic T-lymphocytes (CTL) response.

    Many studies demonstrated that immature DCs can be effectively activated by toll like receptor (TLR) agonists, leading to their maturation and migration to the draining LNs, where they can stimulate effector T cells [17,18].In addition, activation of TLRs on immune cells can promote the secretion of pro-inflammatory cytokines such as IL-6, IL-12 and TNF-α, leading to enhanced innate and adaptive responses [19,20].TLR family members can be divided into endosome-associated and cell-membrane-associated receptors [21].R837 (imiquimod, IMQ) is an endosome-associated agonist for TLR7 and TLR8, which can activate DCs and induce the secretion of various pro-inflammatory factors [22].Monophosphoryl lipid A (MPLA), a detoxified form of lipopolysaccharide (LPS),can interact with membrane-associated TLR4 on DCs and activate DCs.MPLA has been repeatedly shown to enhance the release of pro-inflammatory cytokines and induce stronger T helper 1 (Th1)-biased immune responses [23,24].TLR7/8 signaling depends on myeloid differentiation primary-response gene 88 (MyD88) pathways, while TLR4 signaling is dependent on both of the My88 and TIR-domain-containing adaptor protein inducing IFN-β(TRIF) pathways [25,26].Activation of multiple signaling pathways from both the cell surface and endosome could spatially and temporally induce immune responses that are synergistic [27].TLR7/8 and TLR4 co-stimulation has been reported to significantly increase IL-12 secretion and skew DCs to improve Th1-biased responses [28,29].

    Based on the hypothesis that the immunological efficacy of lipid-polymeric hybrid NPs can be enhancedviaincorporating appropriate molecules, this study aims to compare whether the combination of both endosome-associated and cell-membraneassociated TLR agonist can achieve the highest efficacy in DCsbased immunotherapy.OVA-loaded polymersomes containing both TLR agonist MPLA and IMQ (IMO-PS), single agonist (MO-PS and IO-PS), or without agonist (O-PS) were fabricated and characterized in terms of size and size distribution, zeta potential, and OVA loading amounts.Then, immature DCs were treated with these OVAloaded polymersomes to obtain DCs-based vaccine.The cell viability, cellular uptake and effect of various OVA-loaded polymersomes on DCs maturation, cytokine secretion, and antigen crosspresentation were evaluated.In addition,in vivotracking study was carried out to evaluate the homing ability of DCs-based vaccine.Furthermore,in vivointracellular IFN-γproduction, OVA-specific CTL responses, and prophylactic vaccination effect of various DCsbased vaccines against EG7-OVA tumor model were assessed.Our study revealed that IMO-PS stimulated DCs were more efficient in cancer immunotherapy than MO-PS or IO-PS stimulated DCs,demonstrating enhanced effect of OVA-loaded polymersomes with dual agonists on DCs-based immunotherapy.

    OVA-loaded polymersomes were synthesized and characterized in our study.PCL-PEG-PCL polymersomes (PCEP-PS) co-delivery of immunostimulant molecules and OVA modal antigen were fabricated by a W/O/W method.Using this method, PCEP polymer formed an aqueous hydrophilic PEG core to encapsulate OVA inside and hydrophobic PCL membrane layer to incorporated lipophilic TLR7 agonist IMQ.TLR4 agonist MPLA was anchored into the lipid layer and outside OVA was absorbed on the outer layer of the PS surface by electronic interaction with DOTAP lipid (Fig.S1 in Supporting information).The physical parameters of the formulated PCEP-PS and the loading amounts of OVA were summarized in Table S1 (Supporting information).The average size of the PCEP-PS was detected by dynamic light scattering (DLS) and TEM.Both techniques exhibited that the hydrodynamic diameter of these PCEP-PS was ranged from 250 nm to 300 nm with a PDI of 0.31–0.41.Nanoparticles with this size are reported to effectively activate DCs and induce systemic immune responses compared to bigger particles [30].As shown in Fig.S2A (Supporting information), the TEM image showed that OVA-loaded PS had a spherical shape with some visible particles on the surface, demonstrating successfully adsorption of OVA.The zeta potential was slightly negative, indicating that the OVA was successfully absorbed on the outer layerviacationic DOTAP lipid.OVA was efficiently encapsulated in PCEP-PS with a loading amount ranged from 45 μg/mg to 57 μg/mg PS, indicating their great capability of loading antigen(Table S1).

    In vitroOVA release study was conducted in mimicking normal physiologic microenvironment (PBS, pH 7.4).Representative cumulative release curve of OVA from polymersomes was shown in Fig.S2B (Supporting information).About 20% of the antigen was released from IMO-PS within 24 h and 70% of the antigen was then continuously released for 28 days.Antigen release is one of the most important factors for particle-based vaccination.Prolonging antigen release can enable antigen persistence to immune cells, which is favorable to induce robust T cell responses [31].Meanwhile, initial antigen exposure is also important due to the quick induction of antigen-specific immune responses.The combined quick and slow antigen release from the well-designed IMOPS provided not only initial antigen exposure but also long-term antigen persistence, which was critical to enhance immune responses.

    To ensure the loading of OVA-Cy7 in PECP-PS, we usedin vivoimaging system to acquire NIR fluorescence images of prepared OVA-loaded PS.Fig.S2C (Supporting information) showed that all OVA-loaded PS groups exhibited equivalent fluorescence, while no fluorescence signals were detected in PBS group.To determine the DC labeling efficiency, DCs were incubated with OVA-Cy7 loaded PS at various concentrations (25, 50, 100 or 200 μg/mL) for 16 h and then NIR fluorescence images were obtained.As shown in Fig.S2D (Supporting information), the fluorescence signal intensity increased with the increase of concentration, and intensive NIR fluorescence from the pelleted DCs were observed at concentration higher than 50 μg/mL.

    For DC-based immune therapy, the injected DCs should be capable of keeping viable long enough to migrate to the secondary lymphoid organs and trigger an immune response.Thus, the viability of DCs after incubating with OVA-loaded PS was critical to achieve effective therapy.DC viability was assessed after being treated with various OVA-loaded PS at different OVA concentrations (25 and 50 μg/mL) for 24 and 48 h.As shown in Figs.1A and B, no cytotoxic effect was observed on BMDCs after incubating with free OVA or OVA-loaded PS, indicating the high cytocompatibility and safety of the formulated antigen carriers.

    Fig.1.Cell viability assay and in vitro PCEP-PS uptake.(A, B) Viability of DCs after treating with various OVA-loaded PCEP-PS at different OVA concentrations (A:25 μg/mL; B: 50 μg/mL) for 24 and 48 h.(C) CLSM images of antigen intracellular localization after incubating DCs with free OVA, O-PS, IO-PS, MO-PS and IMO-PS for 16 h.(D) The percentage of antigen uptake by DCs using flow cytometry analysis.???P < 0.001.

    Antigen uptake, the processing and presentation by DCs is an important step for initializing long-time memory and adaptive immunity.CLSM was used to investigate the cellar uptake and lysosome escape.As shown in Fig.1C, obvious green OVA fluorescence was observed in all the PCEP-PS groups, while very weak signal was detected in the free OVA group.This result demonstrated that PCEP-PS greatly facilitated antigen internalization by DCs.In addition, FITC-OVA was perfectly co-localized with lysosomes in free FITC-OVA group, confirming antigen degradation and processingviathe endosome/lysosome pathway.For PCEP-PS groups, although most of FITC-OVA were co-localized with lysosomes, some of them were found in the cytosol.Antigen release into cytosol is beneficial to cross-presentation for the further activation of CD4+and CD8+T cells [32,33].Antigen delivery systems mediated by NPs have been reported to be more efficient in facilitating APCs to crosspresent antigen [34–36].In our study, the lysosome escape might result from the “proton sponge” effect of cationic DOTAP, which could lead to osmotic swelling and lysosome rupture, thereby causing the cytosolic release of antigens [37].The intracellular localization of OVA confirmed that PCEP-PS enabled the endocytic delivery of exogenous antigen for presenting through both MHC I and MHC II pathways.Since TLR7 is primarily localized in the endosomal region of DCs, efficient IMQ released from the membrane of IO-PS and IMO-PS in the endosome could beneficially promote the interaction of TLR7 and IMQ agonist.The effective internalization of IMO-PS by BMDCs could result in the enhanced synergistic immune activation by both TLR4 and TLR7 signaling pathway.

    The antigen uptake capability of free OVA and various OVAloaded PS was further quantitatively analyzed by FACS.As shown in Fig.1D, free OVA group showed poor antigen uptake efficacy.Compared to O-PS, the OVA-loaded PS with TLR4 and/or TLR7 agonist (IO-PS, MO-PS and IMO-PS) showed significantly higher OVA delivery efficiency into DCs (Fig.1D).OVA-loaded PCEP-PS remarkably enhanced antigen uptake by DCs than free OVA did, contributing to that the cationic DOTAP on the outer layer of the PCEPPS could significantly facilitate antigen internalization by DCs [38].Compared with O-PS, MO-PS increased antigen uptake by DCs,which is in accordance with the previous study that MPLA incorporated in NPs enhanced uptake efficiency of antigens by APCsviathe interaction of MPLA and extracellular TLR4 agonist.Furthermore, IMO-PS group exhibited a higher cell uptake capability than IO-PS and MO-PS, implying that PS encapsulating dual TLRs could provide more efficient ligand internalization.The results above demonstrated that our polymersomes could act as an effective antigen-delivery system for preparing DCs-based vaccine.

    As one of the most important APCs, DCs not only can stimulate innate immune responses but also capture, process and present antigens to na?ve T cells to initiate adaptive immune responses.Immature DCs served as antigen-capturing cells, while mature DCs mainly acted as antigen-presenting cells [39].Thus, we analyzed DCs surface markers and secreted cytokines to assess the possible effects of O-PS, IO-PS, MO-PS and IMO-PS on DCs maturation.It was reported that antigen-loaded DCs kept in a resting state in the absence of activation and maturation stimulation, while they could efficiently facilitate adaptive immune responses when being stimulated by danger signals [40].TLR-based immune adjuvants were reported to induce enhanced expression of maturation markers such as costimulatory (CD80, CD86) molecules on DCs [41].The level of CD80 and CD86 was an important index to assess the immune response in DC-based immunotherapy [42].DOTAP liposomes were reported to improve vaccine-induced immune responses by inducing DC maturation [43].In our studies, different OVA-loaded vaccine formulations were cultured with immature DCs for 24 h, and then CD80 and CD86 expression on CD11c+cells were assessed by FACS.As shown in Fig.S3A (Supporting information), IMO-PS significantly induced higher expression of CD80 than free OVA and O-PS group.IO-PS, MO-PS and IMO-PS had higher expression of CD86 than O-PS.More importantly, the MO-PS and IMO-PS with MPLA agonist on the outer layer significantly elevated the expression of CD86 in comparison to other groups.This was probably due to that MO-PS and IMO-PS can mimic bacterial cell walls and enhance phago- and endo-cytosis by DCs as well as increase expression of costimulatory molecules and production of cytokines when MPLA ligating with TLR4 on DCs surface.Our results demonstrated that directly activating TLRs with IMQ and MPLA could synergistically promote DCs maturation.

    To assess whether immunostimulatory molecules (IMQ and/or MPLA) in PCEP-PS could affect cytokines secretion, DCs were cultured with O-PS, IO-PS, MO-PS and IMO-PS for 24 h.Cell culture supernatants were harvested and diluted to evaluate cytokines (TNF-α, IFN-γ) secretion using ELISA.As elucidated in Fig.S3C (Supporting information), the secretion of IFN-γfrom BMDCs treated with IO-PS, MO-PS, and IMO-PS was 2.0-, 2.4-, and 10.0-fold higher than that treated by O-PS group.Meanwhile, the generation of TNF-αwas also greatly augmented in PCEP-PS group with IMQ and/or MPLA agonist.As shown in Fig.S3D (Supporting information), IO-PS, MO-PS, and IMO-PS group yielded 5.5-,8.0-, and 9.0-fold higher TNF-αgeneration than O-PS group.More importantly, IMO-PS with dual agonists significantly elevated both IFN-γand TNF-αproduction compared to IO-PS and MO-PS with only single agonist.The activation of TLR7 signaling had the potential to induce DCs maturation and stimulate the secretion of proinflammatory cytokines [44,45].MPLA treated DCs were reported to be more efficient at producing Th1 cell-derived cytokine, IFN-γ[46].Our results demonstrated that the co-delivery of both TLR7 and TLR4 agonist within the polymersomes had synergistic effect on promoting the production of pro-inflammatory cytokines, which were important in DCs-based immunotherapy.

    Fig.2. In vivo tracking of various OVA-loaded PS treated DCs (A) NIR images obtained at 3, 6, 9, 24 h after injecting free OVA, O-PS and IMO-PS treated DCs(2×106) into the right footpad of C57BL/6 mice.(B) Inguinal lymph node homing of free OVA, O-PS and IMO-PS treated DCs (PBS treated group was set as control).

    Cross-presentation of endocytosed antigens could activate cytotoxic CD8+T cell and then generate antitumor immunity.To evaluate whether the formulated PCEP-PS could enhance antigen MHC I presentation, DCs were first incubated with OVA-loaded PS and then cocultured with OVA-specific LacZ B3Z CD8+T cells hybridoma.B3Z T cells could produceβ-galactosidase during the process of recognizing OVA SIINFEKL, which is presented by MHC I H-2Kb on DCs.And the producedβ-galactosidase was then quantified by CPRG, aβ-galactosidase substrate, to measure antigen crosspresentation.Fig.S3E (Supporting information) showed that compared to free OVA, OVA-loaded PS increased class I antigen presentation which may due to the increased antigen uptake in OVAloaded PS treated DCs.Furthermore, IMO-PS significantly improved the capability of cross-presentation, which may attribute to the combined effect of immune activator IMQ and MPLA.This data indicated that OVA-loaded PCEP-PS with TLR agonist, especially IMOPS with dual agonists, was superior to antigen alone in activating MHC I cross-presentation.

    In DC-based immunotherapy, migration of antigen-loaded DCs from administrated sites to draining LNsvialymphatic vessels is essential for the induction of adaptive immune responses [47].After migrating to LNs, DCs present the processed antigens in peptide form to CD4+and CD8+T cells and then initiate proper immunity against the antigens [48,49].Nevertheless, subcutaneously injected DCs were reported to migrate to the draining lymphoid tissue in a minority, while the majority were remained at the injected site [50].Thus, enhancing DCs migration into LNs is a key process to improve DC-based immunotherapeutic effect.To explore whether IMO-PS treated DCs could achieve a higherin vivomigration to the LNs, DCs (2×106cells) incubated with free OVA, OPS, and IMO-PS were injected into a left hind-leg footpad of the C57BL/6 mouse.Then, fluorescence signals were observed by thein vivoimaging system.As shown in Fig.2A, Cy7-OVA fluorescence appeared in the inguinal LNs 3 h post injection of IMO-PS treated DCs and keep strong at 24 h, whereas free OVA and OPS treated DCs showed a relatively weak fluorescence at 3 h post injection and almost no fluorescence at 24 h, implying gradual migration of IMO-PS treated DCs from the administration site to the draining lymph node through lymphatic vessels.Furthermore, DCs migration was confirmed byex vivoNIR images of dissected inguinal LNs.Fig.2B showed that IMO-PS treated DCs generated the strongest NIR signals, thus demonstrating their effective migration to the draining LNs.However, immature DCs treated with free OVA and O-PS showed a weak signal.The capability of DCs to migrate into draining LNs is essential for DCs to exert functions.Our results demonstrated that IMO-PS treated DCs remained active and achieved migration to LNs after being injected back into mice.

    To confirm antigen-specific T cell responses in immunized mice,intracellular IFN-γwas evaluated by FACS after 96 hex vivostimulation with SIINFEKL peptide.Co-delivery of antigen and adjuvant to DCs was reported to be important to induce strong CD8+T cell immune response [51].TLR activation of DCs is capable of priming antigen-specific CD4+T-helper cells, which are essential to induce antibody responses [52,53].Representative FACS plots and mean frequencies of IFN-γproducing CD4+and CD8+T cells were shown in Fig.3.As for IFN-γ+CD4+T cell in spleen, the percentage in mice immunized with IMO-PS, IO-PS and MO-PS treated DCs was 1.68% ± 0.12%, 1.22% ± 0.14%, and 1.33% ± 0.10%, respectively.On the contrary, PBS, free OVA and O-PS treated DCs immunized mice were significantly lower, with a percentage of 0.52% ± 0.12%,0.53% ± 0.14%, and 0.55% ± 0.11%, respectively.The percentage of IFN-γ+CD8+T cells detected in spleen of mice immunized with IMO-PS treated DCs was 2.44% ± 0.11%, which was significantly higher than IO-PS treated DCs (1.25% ± 0.13%) and MO-PS treated DCs (1.29% ± 0.11%).Additionally, the amount of IFN-γ+CD8+T cells was remarkably lower in mice immunized with PBS, free OVA and O-PS treated DCs, with a percentage of 0.68% ± 0.12%,0.69% ± 0.14% and 0.74% ± 0.11%, respectively.The data suggested that IMO-PS greatly improved the ability of DCs to induce antigenspecific CD8+and CD4+T cell responses.

    The OVA-loaded polymersomes could also induce OVA-specific CTL responsein vivo.CTLs, a type of T lymphocytes, can be activated by mature DCs [54] and kill infected cells or cancer cells by releasing perforin and granzymes [55].Antigen-loaded DC-based vaccines have been considered to directly induce a specific CTL response [56].Considering the increased MHC I presentation and IFN-γproduction by IMO-PS, we speculated that IMO-PS would effectively stimulate vaccine-induced CTL responses.To evaluate the OVA-specific CTL response induced by PS, mice were immunized with various PCEP-PS treated DCs.7 days after administration, splenocytes were obtained and re-stimulated with OVA peptide (SIINFEKL) in 1640 medium containing IL-2 for 72 h.Calcein-AM release assay was then used to evaluate cell viability and assess the CTL activity.The results showed that splenocytes harvested from mice immunized using IMO-PS treated DCs effectively induced CD8+T-mediated tumor cell lysis (Fig.S4A in Supporting information).The enhanced CTL responses could be contributed to the increasement of MHC I presentation and IFN-γproduction by IMO-PS.On the contrary, immunization with free OVA and OPS treated DCs failed to stimulate effective tumor specific CTL responses, in accordance with their poor effect on MHC I presentation and IFN-γsecretionin vitro.Compared with free OVA and OPS, the greatest cytotoxicity against EG7-OVA was achieved at the E:T ratio of 40:1 (Fig.S4B in Supporting information).The above results implied that IMO-PS treated DCs induced efficient antigenspecific CTL activity, demonstrating the synergistic effect of TLR4 and TLR7 signaling pathway on cellular immunity.

    Fig.3.Intracellular IFN-γ production was analyzed by FACS after splenocytes were restimulated with OVA peptide (1 μmol/L) for 96 h (n=3).Representative FACS plots of (A) IFN-γ producing CD4+ T cells and (B) IFN-γ producing CD8+ T cells.Mean frequencies of (C) IFN-γ producing CD4+ T cells and (D) IFN-γ producing CD8+ T cells.?P < 0.05, ??P < 0.01 and ???P < 0.001.

    To investigate the protective efficacy of PCEP-PS treated DCs against progressive EG7-OVA tumor, we immunized C57BL/6 mice with free OVA, O-PS, IO-PS, MO-PS, IMO-PS treated DCs (Fig.4A).PBS treated DCs were set as control group.One week after immunization, 1×106EG7-OVA cells were inoculated subcutaneously on the right back and the percentage of tumor-free mice was evaluated (Fig.4B).All mice in PBS+DCs group developed tumors within 4 days, while the mice injected with free OVA or O-PS treated DCs delayed to develop tumors within 12 days after tumor cell injection.On the contrary, 25% of mice administrated with IO-PS+DCs and MO-PS+DCs remained tumor free on day 54 post-challenge.Strikingly, the tumor free percentage was further increased to 37.5% for the mice vaccinated with IMOPS+DCs (Fig.4B).The survival rate was calculated up to 54 days after tumor inoculation.The mice vaccinated with IMO-PS showed 37.5% survival rate, while the IO-PS and MO-PS treated mice had 25% survival rate (Fig.4C).The results above suggest that IMOPS can elicit potent therapeutic anti-cancer immunity.Remarkably,the tumor-free mice in the IO-PS+DCs, MO-PS+DCs and IMOPS+DCs treated groups were re-challenged with 1×106EG7-OVA tumor cells on day 95 and they remained 100% tumor-free on day 155 (Fig.4D), confirming their capability of exhibiting long-term immunity against tumor reoccurrence.Combination of TLR4 and TLR7 ligands enhanced immune responses by synergistic effectviatriggering different pathways and thus influenced antigen dependent T-cell immune memory.These data above demonstrated that the combinational delivery of OVA, imiquimod and MPLA synergistically triggered anti-tumor immune responsesin vivo, thus achieving superior preventive effect against tumor challenge.

    Fig.4. In vivo protective efficacy of PS treated DCs.(A) Immunization schedule.(B)Percentage of tumor free mice after EG7-OVA tumor cells challenge.(C) Survival rate of EG7-OVA tumor-bearing mice.(D) Re-challenge study on tumor free mice in the IO-PS+DCs, MO-PS+DCs and IMO-PS+DCs group.Na?ve mice (n=6) were used as the control group.

    In summary, we have constructed cationic hybrid polymersomes (IMO-PS) for programmed co-delivery of OVA antigen and dual-adjuvants (IMQ and MPLA) for DC-based immunotherapy against cancer.The IMO-PS dramatically enhanced the OVA uptake in DCs and promoted DCs maturation and cytokines production.In addition, IMO-PS+DCs greatly improved DCs homing ability and OVA-specific CTL responses.Moreover, IMO-PS+DCs significantly extended tumor-free time, effectively suppressed tumor growth and greatly extended median survival time on the prophylactic EG7-OVA tumor model.Impressively, the tumor-free mice were re-challenged with EG7-OVA tumor cells on day 95 and they remained 100% tumor-free at the end of the observation time (155 days).The formulated co-delivery nanoplatform with dual agonists effectively stimulates DCs and holds great promise to be developed as DC-based vaccine for future immunotherapy treatment against cancer.

    Ethical compliance

    All animals were treated according to the regulations and guidelines of the Institute of Biomedical Engineering, Chinese Academy of Medical Science & Peking Union Medical College.

    Declaration of competing interest

    The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

    Acknowledgments

    This work was financially supported by National Natural Science Foundation of China (Nos.82072059 and 82172090),CAMS Initiative for Innovative Medicine (No.2021-I2M-1-058), the Fundamental Research Funds for the Central Universities (Nos.2019PT320028 and 2019-0831-03), Tianjin Municipal Natural Science Foundation (No.20JCYBJC00030).

    Supplementary materials

    Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2022.02.022.

    中文字幕最新亚洲高清| 一本久久中文字幕| 亚洲精品色激情综合| 久久久久久免费高清国产稀缺| 色av中文字幕| bbb黄色大片| 一边摸一边抽搐一进一小说| 51午夜福利影视在线观看| 91av网站免费观看| 色在线成人网| 99re在线观看精品视频| 99国产极品粉嫩在线观看| 波多野结衣高清无吗| 伊人久久大香线蕉亚洲五| 久久久久久免费高清国产稀缺| 人妻夜夜爽99麻豆av| 国产精品久久久久久久电影 | av福利片在线| e午夜精品久久久久久久| 首页视频小说图片口味搜索| 级片在线观看| 国产激情欧美一区二区| 又黄又爽又免费观看的视频| 亚洲电影在线观看av| 麻豆一二三区av精品| 亚洲av成人一区二区三| 在线观看66精品国产| 精品国产亚洲在线| 18禁观看日本| 男人舔奶头视频| 最好的美女福利视频网| 国产成人系列免费观看| www.自偷自拍.com| 国产高清激情床上av| 中出人妻视频一区二区| 岛国在线观看网站| 两人在一起打扑克的视频| 欧美日韩乱码在线| 中亚洲国语对白在线视频| 黑人操中国人逼视频| 亚洲男人天堂网一区| 少妇的丰满在线观看| 女人高潮潮喷娇喘18禁视频| 国内精品久久久久久久电影| 午夜a级毛片| 国内久久婷婷六月综合欲色啪| 日本三级黄在线观看| 久久午夜综合久久蜜桃| 久久精品国产综合久久久| 欧美性长视频在线观看| 日本黄大片高清| 女人高潮潮喷娇喘18禁视频| 国产私拍福利视频在线观看| 久久久精品欧美日韩精品| 69av精品久久久久久| 国产成人影院久久av| 久久香蕉激情| 特大巨黑吊av在线直播| 看免费av毛片| 欧美日韩精品网址| 亚洲电影在线观看av| 国产精品乱码一区二三区的特点| 国产精品亚洲美女久久久| 欧美乱色亚洲激情| 欧美激情久久久久久爽电影| 欧美高清成人免费视频www| 两人在一起打扑克的视频| 99久久国产精品久久久| 麻豆成人午夜福利视频| 老司机午夜福利在线观看视频| 亚洲国产精品久久男人天堂| 非洲黑人性xxxx精品又粗又长| 黄频高清免费视频| 亚洲成av人片免费观看| x7x7x7水蜜桃| 很黄的视频免费| 国产v大片淫在线免费观看| 国产精品永久免费网站| 精品高清国产在线一区| 成人国产综合亚洲| 欧美一区二区精品小视频在线| 丁香欧美五月| 亚洲精品美女久久久久99蜜臀| 麻豆国产97在线/欧美 | 欧美色欧美亚洲另类二区| √禁漫天堂资源中文www| 怎么达到女性高潮| 国产精品免费视频内射| 免费看a级黄色片| 成年版毛片免费区| 一区二区三区高清视频在线| 丁香欧美五月| 久久天躁狠狠躁夜夜2o2o| 亚洲av第一区精品v没综合| 欧美zozozo另类| 青草久久国产| 精品久久蜜臀av无| 国产精品电影一区二区三区| 又紧又爽又黄一区二区| 国产精品一区二区精品视频观看| 亚洲国产高清在线一区二区三| 久久精品人妻少妇| 亚洲专区中文字幕在线| 少妇被粗大的猛进出69影院| 久久中文字幕人妻熟女| 国产真实乱freesex| 久久久国产成人精品二区| 首页视频小说图片口味搜索| 午夜精品一区二区三区免费看| 波多野结衣巨乳人妻| 一本大道久久a久久精品| 国产精品免费视频内射| 欧美+亚洲+日韩+国产| 国产高清激情床上av| 国产黄a三级三级三级人| av视频在线观看入口| 两性夫妻黄色片| 国产区一区二久久| 久久热在线av| www日本在线高清视频| 色哟哟哟哟哟哟| 亚洲自拍偷在线| 国产精品一及| 成人午夜高清在线视频| 亚洲成人久久爱视频| 蜜桃久久精品国产亚洲av| 精品高清国产在线一区| 欧美三级亚洲精品| 日韩精品免费视频一区二区三区| 天天添夜夜摸| 嫁个100分男人电影在线观看| 久久亚洲真实| 1024手机看黄色片| 久久精品国产亚洲av香蕉五月| 国产成人啪精品午夜网站| 午夜成年电影在线免费观看| 正在播放国产对白刺激| 成人国产一区最新在线观看| 国产成人av教育| 亚洲精品粉嫩美女一区| 国产区一区二久久| 免费在线观看完整版高清| 日本黄大片高清| 亚洲中文日韩欧美视频| 午夜福利成人在线免费观看| 久久久久九九精品影院| 欧美日本亚洲视频在线播放| 色在线成人网| 亚洲九九香蕉| 一进一出抽搐动态| 国产精品电影一区二区三区| 每晚都被弄得嗷嗷叫到高潮| 久久99热这里只有精品18| 国产一区二区在线av高清观看| 69av精品久久久久久| 99精品久久久久人妻精品| 日本三级黄在线观看| 国产成人精品久久二区二区免费| 色哟哟哟哟哟哟| 久久亚洲精品不卡| 日本a在线网址| 丝袜人妻中文字幕| 99热这里只有精品一区 | 身体一侧抽搐| 国产精品,欧美在线| 国产免费av片在线观看野外av| 九九热线精品视视频播放| 国产精品久久久久久人妻精品电影| 亚洲成人久久爱视频| 国内久久婷婷六月综合欲色啪| 亚洲av片天天在线观看| 两个人的视频大全免费| 亚洲精品色激情综合| 一个人免费在线观看的高清视频| 在线观看日韩欧美| 最新美女视频免费是黄的| 一本大道久久a久久精品| 午夜视频精品福利| 国产精品久久久久久精品电影| 性色av乱码一区二区三区2| 最近最新免费中文字幕在线| 欧美黄色淫秽网站| 亚洲国产日韩欧美精品在线观看 | 国产精品久久久人人做人人爽| 特大巨黑吊av在线直播| 欧美激情久久久久久爽电影| 欧美在线一区亚洲| 久久这里只有精品中国| 亚洲一区二区三区色噜噜| 国内精品一区二区在线观看| 一本精品99久久精品77| 国产精品九九99| 黄色a级毛片大全视频| 19禁男女啪啪无遮挡网站| 国产亚洲精品久久久久5区| 日韩精品青青久久久久久| 亚洲一区二区三区不卡视频| 国产69精品久久久久777片 | 精品少妇一区二区三区视频日本电影| 啦啦啦观看免费观看视频高清| 亚洲人成电影免费在线| 老汉色av国产亚洲站长工具| 黄色成人免费大全| 好看av亚洲va欧美ⅴa在| 又爽又黄无遮挡网站| 亚洲av日韩精品久久久久久密| 可以在线观看毛片的网站| 大型av网站在线播放| 高潮久久久久久久久久久不卡| 桃红色精品国产亚洲av| 哪里可以看免费的av片| 日本成人三级电影网站| 久久九九热精品免费| 免费观看人在逋| 巨乳人妻的诱惑在线观看| 亚洲 欧美 日韩 在线 免费| 国产久久久一区二区三区| 免费看美女性在线毛片视频| 美女免费视频网站| 欧美日本视频| 特大巨黑吊av在线直播| 九九热线精品视视频播放| 日韩大尺度精品在线看网址| 精品电影一区二区在线| 黄片小视频在线播放| 日本免费一区二区三区高清不卡| 蜜桃久久精品国产亚洲av| 亚洲 欧美一区二区三区| 日韩欧美国产在线观看| 很黄的视频免费| 国产免费av片在线观看野外av| 又粗又爽又猛毛片免费看| 国产精品一区二区三区四区免费观看 | 中文字幕人妻丝袜一区二区| 亚洲中文字幕一区二区三区有码在线看 | 最近最新中文字幕大全电影3| 国产av又大| 久久久久九九精品影院| 99热只有精品国产| 曰老女人黄片| 中文字幕av在线有码专区| 国产片内射在线| 久久午夜综合久久蜜桃| 免费在线观看日本一区| 最近最新中文字幕大全电影3| 精品不卡国产一区二区三区| 天堂动漫精品| 非洲黑人性xxxx精品又粗又长| 亚洲av片天天在线观看| 在线永久观看黄色视频| 成年人黄色毛片网站| 欧美日韩中文字幕国产精品一区二区三区| 国产v大片淫在线免费观看| 欧美成狂野欧美在线观看| 三级毛片av免费| 日本三级黄在线观看| 午夜久久久久精精品| 狂野欧美白嫩少妇大欣赏| 国产黄色小视频在线观看| 亚洲国产精品成人综合色| 欧美成人性av电影在线观看| 99国产精品一区二区蜜桃av| 精品免费久久久久久久清纯| 国产成人精品久久二区二区免费| 十八禁网站免费在线| 国产激情久久老熟女| 日韩免费av在线播放| 亚洲五月天丁香| 91九色精品人成在线观看| 欧美黄色片欧美黄色片| 亚洲精品国产一区二区精华液| 亚洲av成人不卡在线观看播放网| 亚洲成av人片免费观看| 免费无遮挡裸体视频| 嫩草影院精品99| 男女那种视频在线观看| 国产精品久久久久久精品电影| 欧美色欧美亚洲另类二区| 亚洲电影在线观看av| 国产伦人伦偷精品视频| 麻豆一二三区av精品| 国产欧美日韩一区二区三| 欧美3d第一页| 波多野结衣高清无吗| a在线观看视频网站| 精品国内亚洲2022精品成人| 亚洲美女黄片视频| 丝袜人妻中文字幕| 成人精品一区二区免费| av在线播放免费不卡| 亚洲国产精品成人综合色| 国产久久久一区二区三区| 亚洲avbb在线观看| 在线观看66精品国产| 亚洲精品国产精品久久久不卡| 国产成人aa在线观看| 午夜精品一区二区三区免费看| 精品一区二区三区av网在线观看| 老汉色∧v一级毛片| 在线免费观看的www视频| a级毛片a级免费在线| 亚洲一区高清亚洲精品| 国产精品亚洲一级av第二区| 国产亚洲欧美在线一区二区| 人妻久久中文字幕网| 黑人操中国人逼视频| 精华霜和精华液先用哪个| 色精品久久人妻99蜜桃| 久久久国产成人精品二区| 欧美性长视频在线观看| 精品人妻1区二区| 麻豆成人午夜福利视频| 搞女人的毛片| 床上黄色一级片| 久久久久性生活片| www.自偷自拍.com| 久久精品成人免费网站| 在线观看舔阴道视频| 美女大奶头视频| 欧美色视频一区免费| 国产精品亚洲美女久久久| 草草在线视频免费看| 青草久久国产| 欧美精品啪啪一区二区三区| 国产欧美日韩一区二区三| 老司机午夜福利在线观看视频| 亚洲一区二区三区不卡视频| 免费av毛片视频| 麻豆国产av国片精品| 国产亚洲精品av在线| 国产精品香港三级国产av潘金莲| 嫁个100分男人电影在线观看| 成人国语在线视频| 精品不卡国产一区二区三区| 欧美黑人巨大hd| 国产高清videossex| 真人做人爱边吃奶动态| 久久国产精品影院| 久久国产精品影院| 婷婷精品国产亚洲av在线| 日韩欧美精品v在线| 精品国产美女av久久久久小说| 国产亚洲av高清不卡| 久久精品成人免费网站| 午夜福利欧美成人| 久久久久久久午夜电影| 久久天躁狠狠躁夜夜2o2o| 国产69精品久久久久777片 | 成人国产一区最新在线观看| 国产一区二区在线观看日韩 | 五月伊人婷婷丁香| 丝袜美腿诱惑在线| 国产精华一区二区三区| 精品无人区乱码1区二区| 国产亚洲精品av在线| 国产三级中文精品| 国产亚洲欧美在线一区二区| 久久精品综合一区二区三区| 国产麻豆成人av免费视频| 韩国av一区二区三区四区| 免费在线观看影片大全网站| 国产三级在线视频| 草草在线视频免费看| 男女之事视频高清在线观看| 18禁黄网站禁片午夜丰满| 国产人伦9x9x在线观看| 人妻丰满熟妇av一区二区三区| 精品少妇一区二区三区视频日本电影| 久久人人精品亚洲av| 国产三级黄色录像| 最近在线观看免费完整版| 国产人伦9x9x在线观看| 岛国在线观看网站| 美女黄网站色视频| 亚洲成人久久爱视频| 日日夜夜操网爽| 熟女电影av网| 久久久久久人人人人人| www.999成人在线观看| 欧美成狂野欧美在线观看| 精品第一国产精品| 中文字幕久久专区| 色哟哟哟哟哟哟| 丰满人妻一区二区三区视频av | 88av欧美| 亚洲欧美日韩高清专用| 久久国产精品人妻蜜桃| 麻豆久久精品国产亚洲av| 国产高清视频在线观看网站| 成人av在线播放网站| 日本一本二区三区精品| 日韩精品青青久久久久久| 宅男免费午夜| 免费在线观看黄色视频的| 欧美绝顶高潮抽搐喷水| 免费电影在线观看免费观看| 欧美乱妇无乱码| 50天的宝宝边吃奶边哭怎么回事| 久久欧美精品欧美久久欧美| 天天添夜夜摸| 午夜老司机福利片| 精品第一国产精品| 小说图片视频综合网站| 欧美午夜高清在线| 亚洲七黄色美女视频| 女人被狂操c到高潮| 香蕉久久夜色| 999久久久国产精品视频| 听说在线观看完整版免费高清| 丝袜人妻中文字幕| 欧美日韩国产亚洲二区| videosex国产| 成人18禁在线播放| 少妇人妻一区二区三区视频| 女警被强在线播放| 欧美性长视频在线观看| www.999成人在线观看| 午夜成年电影在线免费观看| 91字幕亚洲| 亚洲av日韩精品久久久久久密| 欧美人与性动交α欧美精品济南到| 欧美国产日韩亚洲一区| 亚洲欧美日韩东京热| 两性午夜刺激爽爽歪歪视频在线观看 | 欧美日本视频| 久久久久久人人人人人| 黄色女人牲交| 亚洲精品在线美女| 三级男女做爰猛烈吃奶摸视频| 国产亚洲精品久久久久久毛片| 免费电影在线观看免费观看| 亚洲,欧美精品.| 麻豆av在线久日| 亚洲成a人片在线一区二区| 亚洲专区字幕在线| 亚洲精品美女久久av网站| 国产高清videossex| 国产精品野战在线观看| 国产午夜精品论理片| 国产精品香港三级国产av潘金莲| 国产成人一区二区三区免费视频网站| 国产亚洲精品久久久久久毛片| 麻豆国产97在线/欧美 | 啦啦啦免费观看视频1| 亚洲熟妇熟女久久| 欧美日韩一级在线毛片| 午夜日韩欧美国产| 一区二区三区高清视频在线| 成年版毛片免费区| 成人国语在线视频| 99国产极品粉嫩在线观看| 国产成人av教育| 午夜视频精品福利| 禁无遮挡网站| 欧美又色又爽又黄视频| 欧美成人免费av一区二区三区| 男女下面进入的视频免费午夜| 久久午夜综合久久蜜桃| 黄色视频不卡| 99国产精品一区二区三区| 久久精品91无色码中文字幕| ponron亚洲| 国产单亲对白刺激| 国产免费av片在线观看野外av| 怎么达到女性高潮| 欧美日韩乱码在线| 黄色成人免费大全| 亚洲成人久久爱视频| 少妇人妻一区二区三区视频| 国产又黄又爽又无遮挡在线| 色综合站精品国产| 成人永久免费在线观看视频| 国产精品久久视频播放| 男人舔女人的私密视频| 欧美成人免费av一区二区三区| 日韩欧美一区二区三区在线观看| 久久久久精品国产欧美久久久| 久久精品aⅴ一区二区三区四区| 99热这里只有精品一区 | 亚洲成av人片在线播放无| 亚洲中文av在线| 国产av麻豆久久久久久久| 亚洲精品粉嫩美女一区| 欧美久久黑人一区二区| 欧美在线黄色| 欧美色欧美亚洲另类二区| www.自偷自拍.com| a级毛片在线看网站| 狠狠狠狠99中文字幕| 久久 成人 亚洲| 久久亚洲精品不卡| 亚洲avbb在线观看| 国产三级在线视频| 亚洲成a人片在线一区二区| 国产av在哪里看| 午夜激情福利司机影院| 老汉色∧v一级毛片| 男人的好看免费观看在线视频 | 欧美性猛交黑人性爽| 国产又黄又爽又无遮挡在线| 香蕉av资源在线| 91麻豆av在线| www日本黄色视频网| 免费在线观看成人毛片| 国产精品影院久久| 国产视频内射| 国产av在哪里看| 欧美中文日本在线观看视频| 999久久久国产精品视频| 国产真实乱freesex| 三级国产精品欧美在线观看 | bbb黄色大片| 老熟妇仑乱视频hdxx| 美女 人体艺术 gogo| 好男人电影高清在线观看| 99精品久久久久人妻精品| 精品国产亚洲在线| 制服诱惑二区| 欧美三级亚洲精品| 国产亚洲av嫩草精品影院| 妹子高潮喷水视频| 国产真实乱freesex| 老司机靠b影院| 麻豆国产av国片精品| 国产亚洲精品久久久久久毛片| 99久久无色码亚洲精品果冻| 欧美日韩精品网址| 亚洲欧美一区二区三区黑人| 曰老女人黄片| 母亲3免费完整高清在线观看| 亚洲专区字幕在线| 两个人视频免费观看高清| 不卡av一区二区三区| 亚洲av熟女| 成年版毛片免费区| 久久精品成人免费网站| 色哟哟哟哟哟哟| 18禁黄网站禁片午夜丰满| 午夜福利在线在线| 国产单亲对白刺激| 十八禁网站免费在线| 亚洲va日本ⅴa欧美va伊人久久| 精品欧美国产一区二区三| 美女大奶头视频| 精品国产乱子伦一区二区三区| 久久精品国产亚洲av高清一级| 久热爱精品视频在线9| 久久久精品国产亚洲av高清涩受| 精品国产美女av久久久久小说| 亚洲成av人片在线播放无| a在线观看视频网站| 久久久国产欧美日韩av| 久久热在线av| 日日干狠狠操夜夜爽| 老汉色∧v一级毛片| 亚洲av电影不卡..在线观看| 黄色视频不卡| 变态另类成人亚洲欧美熟女| 夜夜夜夜夜久久久久| 日韩欧美精品v在线| 一级毛片精品| 此物有八面人人有两片| 黄色视频,在线免费观看| 亚洲国产欧美网| 亚洲七黄色美女视频| 一本综合久久免费| 90打野战视频偷拍视频| 看黄色毛片网站| 极品教师在线免费播放| 亚洲一区中文字幕在线| 岛国在线免费视频观看| 亚洲午夜精品一区,二区,三区| 色播亚洲综合网| 麻豆成人av在线观看| 国产精品久久视频播放| 日本黄大片高清| 精品熟女少妇八av免费久了| 97碰自拍视频| 国产69精品久久久久777片 | 男女午夜视频在线观看| 久久草成人影院| 一区福利在线观看| 亚洲国产欧美网| 毛片女人毛片| 午夜a级毛片| 欧美日本视频| 久9热在线精品视频| 国产精品av视频在线免费观看| 韩国av一区二区三区四区| 亚洲五月婷婷丁香| 午夜福利欧美成人| 9191精品国产免费久久| 午夜免费激情av| 18禁黄网站禁片免费观看直播| 亚洲 欧美一区二区三区| 1024视频免费在线观看| 国产亚洲精品第一综合不卡| 看免费av毛片| 欧美zozozo另类| 午夜视频精品福利| 午夜久久久久精精品| 日日干狠狠操夜夜爽| 日韩精品青青久久久久久| www.熟女人妻精品国产| 男女之事视频高清在线观看| 男人舔女人的私密视频| xxx96com| 欧美zozozo另类| 亚洲真实伦在线观看| 欧美最黄视频在线播放免费| 亚洲aⅴ乱码一区二区在线播放 | 美女扒开内裤让男人捅视频| 亚洲国产欧美人成| 国产精品亚洲一级av第二区| 老司机福利观看|